Li Z H, Geller N L
Division of Biostatics, Memorial Sloan-Kettering Cancer Center, New York, New York 10021.
Biometrics. 1991 Jun;47(2):745-50.
Planned interim analysis of randomized clinical trials has been implemented for over a decade. While the initial proposal advocated analyzing after equal numbers of patients were evaluated, a later modification by Lan and DeMets (1983, Biometrika 70, 659-663) allowed for more flexible boundaries. Rather than fixing the times of analysis at equal numbers of patients, they fixed the rate at which overall alpha was used up according to a use function alpha * (t) on t in with alpha * (0) = 0 and alpha * (1) = alpha. Here we consider how flexible Lan and DeMets' procedure is. We show that the choice of alpha * (t) for a particular trial affects the permissible analysis times if other desirable properties of the sequence of nominal significance levels are to hold. To overcome the difficulties posed by patterns of late analysis, piecewise linear convex use functions are proposed.
随机临床试验的计划中期分析已实施了十多年。虽然最初的提议主张在评估相同数量的患者后进行分析,但Lan和DeMets(1983年,《生物统计学》70卷,659 - 663页)后来的修改允许采用更灵活的边界。他们不是将分析时间固定在相同数量的患者时,而是根据关于t的使用函数α*(t)来固定总体α被消耗的速率,其中α*(0)=0且α*(1)=α。在此我们考虑Lan和DeMets方法的灵活性如何。我们表明,如果要保持名义显著性水平序列的其他理想特性,对于特定试验选择α*(t)会影响允许的分析时间。为克服后期分析模式带来的困难,提出了分段线性凸使用函数。